Natalizumab 产品活性：Natalizumab 是一种重组的人源化 IgG4 单克隆抗体，与 α4β1-整联蛋白 (α4β1-integrin) 结合并阻断其与血管细胞粘附分子 1 (VCAM-1) 的相互作用。Natalizumab 可用于复发缓解型多发性硬化症和克罗恩氏病的研究。Natalizumab 也可阻止淋巴细胞进入中枢神经系统，从而防止急性脱髓鞘复发。 产品来源： https://www.medchemexpress.cn/natalizumab.html 研究领域：Cytoskeleton 作用靶点：Integrin In Vitro: Natalizumab, a recombinant, humanized antibody, binds to α4β1-integrin and blocks its interaction with VCAM-1. As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions. Natalizumab may also inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes already present in the CNS, by interrupting the interactions between α4-integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin. In Vivo: Natalizumab binds rapidly and with high affinity to α4-integrin. Maximal binding (≥80% saturation), measured in vitro on isolated lymphocyte membranes, occurred 24 hours after intravenous (IV) doses of natalizumab 1 mg/kg to 6 mg/kg. 相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | Bioactive Compound Library Plus | Antibody Inhibitor Library | Cilengitide | Cyclo(-RGDfK) | Cucurbitacin B | GLPG0187 | E7820 | MK-0429 | CWHM-12 | Pyrintegrin | Lifitegrast | ATN-161 trifluoroacetate salt | Bexotegrast | Arg-Gly-Asp-Ser | Fibronectin | αvβ1 integrin-IN-1 TFA | Tirofiban | A-205804 | iRGD peptide | GPRP acetate | Carotegrast methyl | Eptifibatide | Vedolizumab | RGD peptide (GRGDNP) (TFA) | RGD | Tetrac | Leukadherin-1 | BIO5192 | Cyclo(RGDyK) trifluoroacetate | Etrolizumab 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。